Start the conversation
Oncothyreon Inc. (Nasdaq: ONTY) is a clinical-stage biopharmaceutical company that develops treatments for various types of cancer. Its lead product candidate, Stimuvax, is a cancer vaccine in phase 3 trials for non-small cell lung cancer. But the company also has a pipeline of numerous small-molecule product candidates.
ONTY is not profitable yet, but in the last quarter the company did post an earnings surprise of 30.8% when it reported an earnings per share (EPS) loss of $0.09 compared to estimates of a $0.13 loss. That was also better than the $0.14 loss the company posted the previous quarter.
Shares of ONTY are up more than 24% year to date, and currently trade at $2.18. Brokers surveyed by Thomson/First Call have an average price target of $3.50 set for ONTY, which would be a 61% from today's value.